Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

MANITOBA, Calif.--(BUSINESS WIRE)--FXR Pro Fish, a brand driven by bringing innovation to the water, is proud to announce its partnership with the Bassmaster Elite series as the title sponsor for ...

Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...